Disease Landscape and Forecast Insights

The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo,…

China’s biosimilar market has evolved rapidly over the past four years since the approval of Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab)—in February 2019. As of 2022…

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…

Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets, according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…

Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome inhibitors and…

Clarivate Epidemiology’s coverage of panic disorder comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and the interleukin (IL…

The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s…

Immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, is a rare autoimmune disease affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment…

Atypical antipsychotics—the cornerstone of schizophrenia treatment—are available as oral and injectable (e.g., long-acting injectable [LAI]) formulations in the United States. Many of the oral…

Clarivate Epidemiology’s coverage of neuroendocrine tumors (NETs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Furthermore…